The 2024 European Society for Medical Oncology (ESMO 2024) Annual Meeting will be held from September 13-17 in Barcelona, Spain. At this upcoming ESMO 2024 conference, Dr. Fei Ma from the Cancer Hospital Chinese Academy of Medical Sciences and Peking Union Medical College will present two Mini Oral reports (344MO, 349MO) on the novel Trop-2 antibody-drug conjugate (ADC) ESG401. These two studies not only highlight the significant efficacy of ESG401 in HER2-negative breast cancer with brain metastases but also reveal its broad potential application across different subtypes of metastatic breast cancer. This provides new treatment options for breast cancer patients and opens new directions for the research and development of Trop-2 ADC drugs. Oncology Frontier invited Dr. Fei Ma to introduce the key aspects of these two studies, and we look forward to his exciting presentation at ESMO 2024, contributing Chinese insights and expertise to global breast cancer treatment.

From September 13 to 17, 2024, the highly anticipated European Society for Medical Oncology (ESMO) Annual Meeting took place in Barcelona, Spain. At this prestigious event, three cutting-edge research projects led by Dr. Lin Shen from Peking Cancer Hospital were successfully selected for poster presentations, showcasing the remarkable contributions of Chinese scholars in the field of oncology. Dr. Lin Shen has always emphasized the importance of designing clinical research to solve practical clinical problems, and these three studies exemplify that scientific spirit in action. Oncology Frontier has meticulously compiled the core content of these posters to present readers with an academic feast and to share the latest advancements in oncology.

From August 2 to 4, 2024, the 7th Oncology Precision Diagnosis and Treatment and the 10th Breast Cancer Individualized Treatment Conference (COMB), hosted by the China Cancer Foundation and the Beijing Breast Disease Prevention and Treatment Society, took place in Beijing. This conference focused on the development of individualized precision treatment in the field of breast cancer in China. Dr. Jin Zhang from Tianjin Medical University Cancer Institute and Hospital chaired a session titled “New Concepts in Regional Management of Breast Cancer,” discussing the precise development of comprehensive regional treatment for breast cancer. At the conference, Oncology Frontier had the opportunity to interview Dr. Jin Zhang, who shared insights on the de-escalation in early breast cancer surgery and explored the current status of anti-HER2 therapy and its clinical practice in advanced breast cancer.

At the 2024 European Society for Medical Oncology (ESMO) Annual Congress, Dr. Hitomi Sakai from the Advanced Cancer Translational Research Institute in Japan reported on the significant efficacy of the OLZ-based triple therapy in preventing treatment-related nausea and vomiting (NV) in patients treated with T-DXd, providing an important reference for clinical practice. After the conference, Dr. Hitomi Sakai was interviewed by Oncology Frontier, where she introduced the research process and related results.

At the 2024 ESMO Congress, Dr. Peter Schmid from Barts Cancer Institute, Queen Mary University of London shared the overall survival data from the KEYNOTE-522 study with a follow-up of 75.1 months. The long-term follow-up results of the study showed that the combination of immunotherapy and chemotherapy significantly extended the event-free survival and overall survival of patients with triple-negative breast cancer, reducing the risk of recurrence and death. This breakthrough not only reaffirms the therapeutic position of immunotherapy in early triple-negative breast cancer but also points the way for further optimizing treatment plans in the future, bringing longer survival hopes for patients. Oncology Frontier specially invited Dr. Peter Schmid to share the relevant data.

Xiamen, China, September 25-29, 2024 — The 27th National Clinical Oncology Conference and the 2024 Academic Annual Meeting of the Chinese Society of Clinical Oncology (CSCO) commenced in Xiamen, embracing the theme "Patient-Centric, Shared Future." Jointly organized by the CSCO and the CSCO Foundation, the conference has brought together top experts and elites in oncology from both domestic and international fields to discuss the latest advancements, cutting-edge technologies, and future trends in cancer prevention and treatment.